Leo Pharma brings in old friends and new blood for eczema treatment launch

While Leo Pharma waits for a response to its approval application for eczema treatment Adtralza in the US, it is launching the treatment in the EU, where Head of Europe Monica Shaw can put the experience from launching psoriaris treatment Kyntheum to good use.

Monica Shaw, an Executive Vice President, Head of Europe, Canada and Australia at Leo Pharma | Photo: Leo Pharma / PR

Leo Pharma is making the most of its EU approval for eczema treatment Adtralza (tralokinumab) coming in two weeks earlier than expected.

Monica Shaw, an Executive Vice President at Leo Pharma who was appointed Head of Europe a little over a year ago, is responsible for the launch of the treatment in Europe, which will also be the first launch of the drug following a rejection of the drug by the FDA earlier in the year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs